[
  {
    "ts": "2026-01-11T03:11:24+00:00",
    "headline": "What adidas (XTRA:ADS)'s Rare Bank of America Sell Rating Says About Its Competitive Moat",
    "summary": "In early January 2026, Bank of America issued a rare sell rating on adidas, citing slowing growth and intensifying competition from brands such as Nike, On, Asics, and Puma. The downgrade underscores how shifting casualwear trends and a crowded performance footwear market are testing adidas’ ability to defend its brand position. Next, we’ll examine how Bank of America’s concerns about mounting competition could influence adidas’ existing investment narrative and outlook. Outshine the giants:...",
    "url": "https://finance.yahoo.com/news/adidas-xtra-ads-rare-bank-031124571.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "a535fea4-677b-3fb6-852c-91d5ef891615",
      "content": {
        "id": "a535fea4-677b-3fb6-852c-91d5ef891615",
        "contentType": "STORY",
        "title": "What adidas (XTRA:ADS)'s Rare Bank of America Sell Rating Says About Its Competitive Moat",
        "description": "",
        "summary": "In early January 2026, Bank of America issued a rare sell rating on adidas, citing slowing growth and intensifying competition from brands such as Nike, On, Asics, and Puma. The downgrade underscores how shifting casualwear trends and a crowded performance footwear market are testing adidas’ ability to defend its brand position. Next, we’ll examine how Bank of America’s concerns about mounting competition could influence adidas’ existing investment narrative and outlook. Outshine the giants:...",
        "pubDate": "2026-01-11T03:11:24Z",
        "displayTime": "2026-01-11T03:11:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/cb577674b7e557d971f138507100a6d5",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5FuWnDACU..5OK.AroKx5g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/cb577674b7e557d971f138507100a6d5.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K2z4xhhhuqblfIvoH2uQcA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/cb577674b7e557d971f138507100a6d5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/adidas-xtra-ads-rare-bank-031124571.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/adidas-xtra-ads-rare-bank-031124571.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAC"
            },
            {
              "symbol": "ADDDF"
            },
            {
              "symbol": "ADDYY"
            },
            {
              "symbol": "NKE"
            },
            {
              "symbol": "ASCCF"
            },
            {
              "symbol": "PMMAF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-11T05:10:20+00:00",
    "headline": "The Bull Case For Amphastar Pharmaceuticals (AMPH) Could Change Following New BofA Coverage And JPM Spotlight",
    "summary": "BofA Securities recently initiated coverage on Amphastar Pharmaceuticals with a hold rating and a US$30 target, while the company’s leadership also presented at the J.P. Morgan 2026 Healthcare Conference, highlighting its portfolio of generic and proprietary injectable, inhalation, and intranasal products. Together, the fresh analyst coverage and conference appearance have drawn new attention to Amphastar’s investment in capacity expansion and its proprietary product pipeline. With BofA’s...",
    "url": "https://finance.yahoo.com/news/bull-case-amphastar-pharmaceuticals-amph-051020077.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "19796c58-d41c-30c4-828b-a07c0d1528d7",
      "content": {
        "id": "19796c58-d41c-30c4-828b-a07c0d1528d7",
        "contentType": "STORY",
        "title": "The Bull Case For Amphastar Pharmaceuticals (AMPH) Could Change Following New BofA Coverage And JPM Spotlight",
        "description": "",
        "summary": "BofA Securities recently initiated coverage on Amphastar Pharmaceuticals with a hold rating and a US$30 target, while the company’s leadership also presented at the J.P. Morgan 2026 Healthcare Conference, highlighting its portfolio of generic and proprietary injectable, inhalation, and intranasal products. Together, the fresh analyst coverage and conference appearance have drawn new attention to Amphastar’s investment in capacity expansion and its proprietary product pipeline. With BofA’s...",
        "pubDate": "2026-01-11T05:10:20Z",
        "displayTime": "2026-01-11T05:10:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pVOKMAerbRsXv56pHka6Lw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmyGBi4taxQExvvwka_9KQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-amphastar-pharmaceuticals-amph-051020077.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-amphastar-pharmaceuticals-amph-051020077.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMPH"
            },
            {
              "symbol": "BAC"
            },
            {
              "symbol": "JPM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]